Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp deletion in exon2.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IFI44L, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The interferon-induced protein 44-like (IFI44L) is a protein encoded by the IFI44L gene. It is also known as IFI44L protein or sometimes simply IFI44L. This protein has a molecular mass of around 49 kDa. IFI44L is broadly expressed in many tissues with higher expression in blood and spleen. Mechanically IFI44L contributes to the antiviral response by being induced by type I and type II interferons. Its exact mechanism of action involves modulation in response to viral infection although full details of how it works are still not completely understood.
Biological function summary
IFI44L plays an active role in the body's defense against viral infections. It participates as part of the broader immune response. While not being recognized as a classic element of a large protein complex it interacts with cellular machinery responsible for immune regulation and interferon signaling. This protein contributes towards the establishment of an antiviral state in affected cells through mechanisms which are yet to be completely defined. Its inducible nature makes it an important part of how cells respond to foreign viral components.
Pathways
This target connects to the interferon signaling pathway which is important for antiviral defenses. IFI44L plays a significant role in the broader cytokine signaling pathways particularly those related to type I interferon responses. It interacts with proteins such as MX1 and IFIT1 which are important elements of the interfacing network that responds to viral challenges in the cell. These relationships help in sustaining a robust antiviral state within the host.
IFI44L is linked to conditions like systemic lupus erythematosus (SLE) and viral infections such as hepatitis C. This can be due to its regulatory role in immune responses and interferon signaling. In SLE where interferon activity is often dysregulated IFI44L expression can be elevated. It also connects with proteins like IFI27 and ISG15 which are similarly upregulated in response to viral infections and are implicated in the pathogenesis of these diseases. Understanding IFI44L's function and interactions further aids in exploring therapeutic approaches for these conditions.
